Research Library / Blends / Tesamorelin + Ipamorelin
Blends researchTesamorelin + Ipamorelin
GHRH analog + GHSR agonist blend
A vendor blend combining an approved indication-specific medicine with an unapproved secretagogue; the mixture itself is not an approved product. The listed community example (common bedtime blend schedule) describes 1 mg / 200 mcg per administration, once daily, via subcutaneous; this is not a validated dosing recommendation. Amounts retain their component order and must not be read as total blend mass. An illustrative 12 mg total-blend vial at an assumed 2 mL final volume yields 6 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 12mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 6mg/mL · conditional arithmetic
- One U-100 marking
- 60mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryClinicalTrials.gov| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Common bedtime blend schedule | 1 mg / 200 mcg | One administration/day | Once daily | Bedtime, often fasted | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
10 example portions per vial
10 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
1.2 mg total blend (1 mg/200 mcg) · 6 mg/mL · 0.2 mL · 20 units
Assumes a specifically labeled 10 mg tesamorelin + 2 mg ipamorelin vial. At 6 mg total blend/mL, the fixed 1 mg/200 mcg ratio equals 0.20 mL (20 U-100 units). No controlled human trial validates this blend, and other ratios require different math. A finished tesamorelin/ipamorelin blend has its own compatibility requirements. Tesamorelin labels and ipamorelin salt/formulation information do not validate an arbitrary same-vial mixture. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
Supply total not calculated
12 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific
No single, consistently reported subcutaneous amount-and-frequency pair is available for a responsible automatic supply calculation.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Tesamorelin + Ipamorelin · GHRH analog + GHSR agonist blend
- Evidence / status
- Unestablished blend. No FDA-approved combination product
- Clinical route, frequency & duration
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- GH-axis stimulation, recovery, sleep, and body-composition discussions combining GHRH and ghrelin-receptor signaling.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
A finished tesamorelin/ipamorelin blend has its own compatibility requirements. Tesamorelin labels and ipamorelin salt/formulation information do not validate an arbitrary same-vial mixture.
Other vehicles and approaches discussed
Commercial accounts describe dissolution problems and acidified approaches. Neither EGRIFTA diluent nor an acid/PBS recipe can be assigned universally to this blend.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Blend-specific dissolution / compatibility uncertainty
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Blend-specific dissolution / compatibility uncertainty
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Combined GHRHR and GHSR stimulation
A vendor blend combining an approved indication-specific medicine with an unapproved secretagogue; the mixture itself is not an approved product.
Community-reported purpose
GH-axis stimulation, recovery, sleep, and body-composition discussions combining GHRH and ghrelin-receptor signaling.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Evidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Tesamorelin labeling and ipamorelin research do not establish safety, efficacy or dosing for the blend.
Development and regulatory status
No FDA-approved combination product
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Tesamorelin + Ipamorelin?
A vendor blend combining an approved indication-specific medicine with an unapproved secretagogue; the mixture itself is not an approved product.
Combined GHRHR and GHSR stimulation
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
A finished tesamorelin/ipamorelin blend has its own compatibility requirements. Tesamorelin labels and ipamorelin salt/formulation information do not validate an arbitrary same-vial mixture.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeClinicalTrials.gov: Evidence landscape
- Product labelEGRIFTA SV FDA label
- Product labelEGRIFTA WR FDA label
- Regulator assessmentFDA ipamorelin assessment (2024)
- Community/vendor report — unvalidatedVendor dissolution/gelling report
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.